Last reviewed · How we verify

NCT03161418

Study of the Safety of KSP Heptapeptide (KSP-910638G)

Completed Phase 1 Last updated 5 December 2017
What this trial tests

Phase 1 trial testing KSP-910638G, 0.4 mg in Healthy Adults in 26 participants. Completed in 20 September 2017.

Timeline
21 June 2017
Primary endpoint
20 September 2017
20 September 2017

Quick facts

Lead sponsorUniversity of Michigan
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposeother
Enrollment26
Start date21 June 2017
Primary completion20 September 2017
Estimated completion20 September 2017
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Michigan

Who can join

Adults 25 to 100, any sex, with Healthy Adults. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety of orally administered KSP-910638G, a topically administered li-cor IRDye800CW labeled heptapeptide specific for human epithelial growth factor receptor 2 (HER2).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Targeted Optical Imaging Agents in Cancer: Focus on Clinical Applications.
    Joshi BP, Wang TD. · · 2018 · cited 63× · PMID 30224903 · DOI 10.1155/2018/2015237

Verify or expand the search:

Other recruiting trials for Healthy Adults

Currently open trials in the same condition.

Other University of Michigan trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03161418.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing